Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRDNYSE / NASDAQHealthcareSmall cap

$0.99+$0.04 (+4.5%)

Last close · Data as of Nov 20, 2026

Market cap
$28.9M
P/E
-1.6x
EV / EBITDA
-0.3x
Revenue
$0.00
ROCE
-127.2%

-74.1% over the last year

Tvardi Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-0.3%
3M
-46.0%
6M
-74.3%
1Y
-74.1%
5Y
Hidden
  • This period includes a one-day price step on 13 Oct 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change +$0.04 (+4.5%) from $0.95 to $0.99 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TVRD, bought on each weekday since 2021.

News & filings

What Tvardi Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 18.2 million US dollars in fiscal 2025.

Strengths (1)

  • Cash on the balance sheet equals 72% of the company's market value.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.

Read moreShow less

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Sector
Healthcare
Shares outstanding
9.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$28.9M
P/E
-1.6x
P/B
1.4x
EV / EBITDA
-0.3x
52-week high
$5.00
52-week low
$0.79

Profitability

ROE
-87.0%
ROCE
-127.2%
ROIC
-5116.4%
ROA
-56.8%

Growth

Revenue
$0.00
Net profit growth, 1Y
-38.0%
Free cash flow
-$23.5M

Solvency

Current ratio
2.86
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
1.29
Cash / Market cap
71.8%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Tvardi Therapeutics, Inc. revenue and net profit by fiscal year
Tvardi Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$20.5M
FY2023$0.00-$17.3M
FY2024$0.00-$29.4M
FY2025$0.00-$18.2M

Cash flows

FY2025: -$23.5M from operations, -$23.5M free after investment (dashed).

Tvardi Therapeutics, Inc. operating and free cash flow by fiscal year
Tvardi Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$17.9M-$17.9M
FY2023-$21.0M-$21.0M
FY2024-$18.3M-$18.3M
FY2025-$23.5M-$23.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$26.7M
Net profit
-$18.2M
Cash from operations
-$23.5M
Free cash flow
-$23.5M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$26.7M-$18.2M-$23.5M-87.0%—-38.0%

Monthly returns

Month-by-month returns of TVRD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$32.1M
Liabilities$11.1M
Equity$20.9M
Paid-in capital$131.4M
Retained earnings-$110.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TVRD highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Tvardi Therapeutics, Inc., Actuate Therapeutics, Inc. Common stock, Tevogen Bio Holdings Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Tvardi Therapeutics, Inc.TVRDthis company$28.9M-1.6x1.4x-87.0%-0.3x
DocGo Inc.DCGO$56.3M-0.3x0.4x-126.7%-0.5x
aTyr Pharma, Inc.ATYR$50.3M-0.7x0.7x-109.8%-0.7x
Myomo, Inc.MYO$49.8M-3.2x4.4x-136.6%-4.4x
Actuate Therapeutics, Inc. Common stockACTU$46.4M-2.1x5.9x-280.5%—
Accuray IncorporatedARAY$43.5M-27.3x0.5x-2.0%8.0x
Gossamer Bio, Inc.GOSS$41.7M-0.2x-0.3x138.8%-1.3x
Tevogen Bio Holdings Inc.TVGN$41.3M-1.6x-2.4x154.2%-1.9x
INmune Bio Inc.INMB$35.9M-0.8x1.5x-195.3%-0.4x
Peer median—-1.2x0.6x-118.2%-0.7x

Year-to-date ROI

TVRD since 1 January, against earlier years.

Historical volatility

TVRD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$26.8M
Research and developmentResearch And Development$18.0M
Total expensesTotal Expenses$26.8M
Pretax incomePretax Income-$18.2M

Learn while you research

Academy chapters picked for Tvardi Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →